Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
NEW JCM GROUP
300157
5
Shenzhen S-king Intelligent Equipment
688328
US OptionsDetailed Quotes
NVS250516C135000
- 0.00
- 0.000.00%
15min DelayClose Apr 28 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest135.00Strike Price0.00Turnover0.00%IV19.86%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma750.87Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Novartis AG Newsroom
Novartis (NVS.US) has submitted a new indication for its radioactive cancer therapy for market approval in China.
On April 28, the latest announcement on the CDE official website stated that Novartis (NVS.US) has had its application for a new indication for the lutetium [177Lu] tetrofosmin injection accepted.
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Earnings Week Ahead: MSFT, AAPL, META, AMZN, QCOM, PFE, MA, V, PYPL, ROKU, MCD, SBUX, KO, and More
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
Catalyst Watch: Apple, Amazon & Microsoft's Earnings Confessions, Meta's LlamaCon and the Jobs Report
Report Says 25% Pharma Tariff Would Raise US Drug Prices by $51 Billion Annually, Reuters Reports
Novartis AG: Stable Outlook With Mixed Product Performance and Favorable Forex Impact Justifies Hold Rating
Novartis Expected to Post Higher Profit, Sales -- Earnings Preview
Harrow Authorizes Nordic Group Unit to Sell Generic Version of Maxitrol Eye Treatment
Earnings Preview: Novartis AG to Report Financial Results Pre-market on April 29
Novartis, Sanofi CEOs Push for EU Drug Pricing Reforms Amid Tariff Concerns
AstraZeneca CEO Urges Europe to Spend More on Health or Risk Falling Behind -- Market Talk
European pharmaceutical giants are calling for an increase in pharmaceutical prices to the same level as in the USA.
The CEOs of the two major pharmaceutical giants in Europe, Novartis and Sanofi, stated in an open letter on Wednesday that in order to attract investment, the EU should allow pharmaceutical prices to rise to the levels found in the USA. Pharmaceutical prices in the USA are the highest in the world, often nearly three times that of other developed countries. Novartis CEO Vas Narasimhan and Sanofi CEO Paul Hudson wrote, "Price controls and austerity measures in Europe have reduced the attractiveness of its market." They added, "In the context of declining biopharmaceutical competitiveness in Europe, uncertainty about tariffs further diminishes the motivation to invest in the EU." They believe that EU
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Trump Mulls Cutting US Drug Prices to International Levels, Reuters Reports
AlphaValue/Baader Europe Lifts Novartis Price Target on Upbeat Earnings Outlook
The Swiss pharmaceutical company Roche plans to invest 50 billion USD in the USA over the next five years for its pharmaceutical and diagnostics business.
Roche Holdings will invest 50 billion USD in the USA over the next five years for pharmaceutical and diagnostic Business. In the context of Donald Trump's push for a protectionist trade agenda, this Swiss pharmaceutical company joins a number of others in increasing investment in the USA. Roche stated in a press release on Tuesday that the plans include expanding and upgrading manufacturing and distribution capabilities in Kentucky, Indiana, New Jersey, Oregon, and California. Roche also plans to establish a production facility to support the scale-up of next-generation weight loss drugs, but has not disclosed the location of the factory. This commitment is similar to actions taken by Swiss competitor Novartis, which earlier this month...
S&P 500, Nasdaq Futures Rise After Stocks Dip Amid Trump's Jabs At Powell, Strong Yen Gives Nikkei A Volatile Start
Catalyst Watch: Spotlight on Tesla, Alphabet Earnings, AACR Drug Data, and Global PMI Reports
Hikma Acquires Rights to Generic Version of Novartis' Mekinist
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
